(Q42253633)

19 October 2017

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines (English)

1 reference

19 October 2017

1 reference

2

Per Eystein Lønning

1 reference

19 October 2017

3

Stian Knappskog

1 reference

19 October 2017

1

Johanna Huun

1 reference

19 October 2017

22 May 2017

1 reference

19 October 2017

1 reference

19 October 2017

3

1 reference

19 October 2017

17026

1 reference

Creative Commons Attribution 4.0 International

19 October 2017

start time

22 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/cddiscovery.2017.26

0 references

cites work

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Antitumor mechanisms when pRb and p53 are genetically inactivated

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

The mutational landscape of lethal castration-resistant prostate cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Alterations of the retinoblastoma gene in metastatic breast cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

TP53 mutation and survival in chronic lymphocytic leukemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Integrative genomic profiling of human prostate cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Tailoring to RB: tumour suppressor status and therapeutic response

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Cellular mechanisms of tumour suppression by the retinoblastoma gene.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Restoration of p53 function leads to tumour regression in vivo

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Live or let die: the cell's response to p53

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

CHK2 kinase--a busy messenger.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Apoptosis, p53, and tumor cell sensitivity to anticancer agents

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

pRB plays an essential role in cell cycle arrest induced by DNA damage

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

The retinoblastoma tumor suppressor protein.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Molecular stratification of triple-negative breast cancers

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5439126

Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases

17 August 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDDISCOVERY.2017.26

7 January 2021

A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCDDISCOVERY.2017.26

7 January 2021

Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells

1 reference

https://api.crossref.org/works/10.1038%2FCDDISCOVERY.2017.26

7 January 2021

Structural rearrangement of the retinoblastoma gene in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FCDDISCOVERY.2017.26

7 January 2021

10.1038/CDDISCOVERY.2017.26

Identifiers

DOI

1 reference

19 October 2017

1 reference

PMC publication ID

5439126

19 October 2017

PubMed publication ID

28580174

1 reference

PMC publication ID

5439126